COVERA-HS Drug Patent Profile
✉ Email this page to a colleague
When do Covera-hs patents expire, and when can generic versions of Covera-hs launch?
Covera-hs is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in COVERA-HS is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Covera-hs
A generic version of COVERA-HS was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COVERA-HS?
- What are the global sales for COVERA-HS?
- What is Average Wholesale Price for COVERA-HS?
Summary for COVERA-HS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 4 |
| DailyMed Link: | COVERA-HS at DailyMed |
Recent Clinical Trials for COVERA-HS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
| Gillette Children's Specialty Healthcare | Phase 2 |
| Dartmouth-Hitchcock Medical Center | Phase 2 |
US Patents and Regulatory Information for COVERA-HS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COVERA-HS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COVERA-HS
See the table below for patents covering COVERA-HS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 9100838 | FORMA DE DOSIS PARA PATRONES DE VARIACION DE TIEMPO DE SUMINISTRO DE DROGA | ⤷ Sign Up |
| Japan | H07116018 | ⤷ Sign Up | |
| Japan | 2796433 | ⤷ Sign Up | |
| France | 2622798 | FORME D'APPORT DOSE ET DISPOSITIF OSMOTIQUE D'ADMINISTRATION D'UN MEDICAMENT POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES | ⤷ Sign Up |
| Australia | 2251183 | ⤷ Sign Up | |
| Belgium | 898819 | ⤷ Sign Up | |
| Ireland | 56515 | OSMOTIC DEVICE WITH DUAL THERMODYNAMIC ACTIVITY | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
